Israel-based Teva Pharmaceutical Industries Ltd. (TEVA – Free Report) is a global pharmaceutical company with a strong presence in the generics as well as branded markets. The company’s branded products include Copaxone (multiple sclerosis), Azilect (Parkinson’s disease), Austedo (chorea associated with Huntington’s disease and tardive dyskinesia) and respiratory products like ProAir and Qvar. 

Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Nonetheless, Teva is progressing well on its strategic/restructuring initiatives to revive growth.

Teva’s earnings surpassed expectations in three of the last four quarters, resulting in an average positive surprise of 16.18%.

Currently, TEVA has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. 

We have highlighted some of the key stats from this just-revealed announcement below:

Earnings Beat: Teva’s third-quarter earnings came in at 68 cents per share which beat consensus estimate of 55 cents.

Revenues Miss: Teva posted revenues of $4.53 billion, which missed consensus estimates of $4.58 billion. Sales declined 19% (down 18% in constant currency terms) year over year.

Key Statistics: North America segment sales were $2.27 billion, down 26% year over year due to pricing erosion in U.S. generics market, lower sales of Copaxone as well as some other branded drugs and divestiture of some non-core assets in the Women’s Health business. In the United States, revenues declined 27% to $2.1 billion.

Lead branded product, Copaxone, posted sales of $463 million in North America, down 43% year over year due to generic competition for the 20 mg as well as the 40 mg formulation. Sales of generic products declined 25% to $922 million.